All articles tagged with #efzofitimod
aTyr Pharma's experimental drug efzofitimod failed to meet its primary goal in a late-stage trial for pulmonary sarcoidosis, causing its shares to plummet over 80% to a record low, though the company sees potential benefits and plans to discuss next steps with the FDA.
aTyr Pharma's Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed clinical benefits such as improved lung scores and steroid withdrawal, leading the company to plan discussions with the FDA on future development.
aTyr Pharma's Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint of reducing corticosteroid dose at week 48, but secondary outcomes showed some benefits such as higher rates of steroid withdrawal and improved lung scores. The drug was well-tolerated, and the company plans to consult with the FDA to determine the next steps.